{"id":86561,"date":"2023-11-20T08:33:07","date_gmt":"2023-11-20T13:33:07","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/bayer-stops-late-stage-study-for-stroke-prevention-due-to-lack-of-efficacy\/"},"modified":"2023-11-20T08:33:08","modified_gmt":"2023-11-20T13:33:08","slug":"bayer-stops-late-stage-study-for-stroke-prevention-due-to-lack-of-efficacy","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=86561","title":{"rendered":"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy"},"content":{"rendered":"<div id=\"js-article__body\" itemprop=\"articleBody\" data-sbid=\"MW-BT-CO-20231120-700298\">\n<div class=\"snippet__body\">\n<p>By Helena Smolak<\/p>\n<p>Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for patients with atrial fibrillation due to lack of efficacy.<\/p>\n<p>The German pharmaceutical-and-agricultural group said late Sunday that the decision is based on a recommendation by the independent&#8230;\n      <\/p>\n<\/p><\/div>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.marketwatch.com\/story\/bayer-stops-late-stage-study-for-stroke-prevention-due-to-lack-of-efficacy-2b7909e5?mod=investing\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By Helena Smolak Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for patients with atrial fibrillation due to lack of efficacy. The German pharmaceutical-and-agricultural group said late Sunday that the decision is based on a recommendation by the independent&#8230; Read the full article [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":86195,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-86561","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy | iFintechWorld<\/title>\n<meta name=\"description\" content=\"By Helena Smolak Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=86561\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"By Helena Smolak Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=86561\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-20T13:33:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-20T13:33:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/11\/mw_logo_social.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=86561#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=86561\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy\",\"datePublished\":\"2023-11-20T13:33:07+00:00\",\"dateModified\":\"2023-11-20T13:33:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=86561\"},\"wordCount\":67,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=86561#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=86561\",\"url\":\"https:\/\/ifintechworld.com\/?p=86561\",\"name\":\"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-11-20T13:33:07+00:00\",\"dateModified\":\"2023-11-20T13:33:08+00:00\",\"description\":\"By Helena Smolak Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=86561#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=86561\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=86561#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy | iFintechWorld","description":"By Helena Smolak Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=86561","og_locale":"en_US","og_type":"article","og_title":"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy | iFintechWorld","og_description":"By Helena Smolak Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for","og_url":"https:\/\/ifintechworld.com\/?p=86561","og_site_name":"iFintechWorld","article_published_time":"2023-11-20T13:33:07+00:00","article_modified_time":"2023-11-20T13:33:08+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/11\/mw_logo_social.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=86561#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=86561"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy","datePublished":"2023-11-20T13:33:07+00:00","dateModified":"2023-11-20T13:33:08+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=86561"},"wordCount":67,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=86561#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=86561","url":"https:\/\/ifintechworld.com\/?p=86561","name":"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-11-20T13:33:07+00:00","dateModified":"2023-11-20T13:33:08+00:00","description":"By Helena Smolak Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=86561#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=86561"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=86561#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/86561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=86561"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/86561\/revisions"}],"predecessor-version":[{"id":86562,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/86561\/revisions\/86562"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/86195"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=86561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=86561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=86561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}